文献速递艾滋病与性传播感染

性别、年龄与体成分对长效注射利匹韦林和卡博特韦谷浓度的影响

Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

结果显示卡博特韦谷浓度在女性、65岁以上者及骨骼肌量较低者中更高,而利匹韦林谷浓度与这些因素无显著关联。

要点

  • 卡博特韦谷浓度受性别、年龄和肌肉量显著影响,利匹韦林不受影响
  • 女性卡博特韦谷浓度高于男性(3285±921 vs 2096±775 ng/mL)
  • 治疗药物监测结合体成分评估可能有助于优化给药间期调整

核心结论

  • 性别、年龄和肌肉量显著影响接受长效注射治疗的HIV感染者卡博特韦谷浓度,但不影响利匹韦林谷浓度。
  • 治疗药物监测结合体成分评估可能有助于优化给药间期调整。

研究设计与样本

  • 体成分通过生物电阻抗分析估算,药物水平与临床变量的关联采用单因素和多因素回归分析。

主要发现

  • 利匹韦林和卡博特韦谷浓度个体内变异为中等程度(28-30%),低于治疗阈值的样本不足1%。
  • 利匹韦林浓度与人口学或体成分变量无显著关联;多因素分析确认年龄、性别和肌肉量为卡博特韦暴露的独立预测因素。

临床怎么用

  • 对接受长效注射卡博特韦的HIV感染者,可关注女性、高龄及肌肉量较低者的药物暴露水平。
  • 必要时结合治疗药物监测与体成分评估,辅助调整给药间期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Considerable inter-individual variability in the pharmacokinetics of long-acting injectable (LAI) rilpivirine and cabotegravir has been reported. Here, we sought to evaluate intra- and inter-individual variability of rilpivirine and cabotegravir plasma trough concentrations and to assess the influence of demographic factors and body composition on drug exposure in people with HIV (PWH) receiving LAI therapy. METHODS: This retrospective observational study included PWH treated with LAI rilpivirine and cabotegravir for ≥16 months, with at least three consecutive plasma trough concentration assessments. Body composition was estimated by bioelectrical impedance analysis. Associations between drug levels and clinical variables were analysed using univariate and multivariate regression analysis. RESULTS: Forty-eight PWH were included (mean age 47 ± 15 years, 17% females). Rilpivirine and cabotegravir showed moderate intra-individual variability in trough concentrations (28-30%), with <1% of samples below the therapeutic threshold. Cabotegravir trough concentrations were significantly higher in women than in men (3285 ± 921 versus 2096 ± 775 ng/mL; P < 0001) and in participants aged >65 years compared with younger individuals (2826 ± 455 ng/mL versus 2119 ± 1006 ng/mL; P = 0044); in addition, cabotegravir levels inversely correlated with skeletal muscle mass (r = -0.45; P = 0.008) and bone mass (r = -0.47; P = 0006). On the contrary, rilpivirine concentrations showed no significant associations with demographic or body composition variables. Multivariate analysis confirmed age, sex and muscle mass as independent predictors of cabotegravir exposure. CONCLUSIONS: Sex, age and muscle mass significantly influence cabotegravir-but not rilpivirine-trough concentrations in PWH receiving LAI therapy. Therapeutic drug monitoring combined with body composition assessment may help to optimize dosing interval adjustment.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Cossu MV, Cattaneo D, Soloperto S, et al. Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy. J Antimicrob Chemother. 2026. PMID: 41614614. doi:10.1093/jac/dkag024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。